Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

From focal lesion to fat sparing: Unmasking Zieve's syndrome with clinical vigilance

Leena Alhusari, Mahmood Aldapt, Moh'D Masoudi et al. Nov 03, 2025 pp. 6445-6445 10.1182/blood-2025-6445

Abstract Zieve's syndrome is a rare and often overlooked complication of alcohol misuse, likely under-recognized due to limited physician aw...

Provider practices and preparedness for gene therapy in pediatric sickle cell disease: A national survey of pediatric hematologists

Cecile Karsenty, Titilope Fasipe, Venee N. Tubman et al. Nov 03, 2025 pp. 4378-4378 10.1182/blood-2025-4378

Abstract Introduction: Sickle cell disease (SCD) is a severe, life-limiting genetic disorder affecting over 100,000 individuals in the U.S....

Access barriers and treatment patterns in Philadelphia-negative myeloproliferative neoplasms (Ph- MPN): Insights from a brazilian physician survey

Carlos Murilo Barbosa, Carlos Augusto Sousa, Mario Junior et al. Nov 03, 2025 pp. 7356-7356 10.1182/blood-2025-7356

Abstract Introduction: Effective management of Philadelphia-negative myeloproliferative neoplasms (Ph- MPNs)—including polycythemia vera (PV...

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Narendranath Epperla, Allison Bock, Yizhe Xu et al. Nov 03, 2025 pp. 8241-8241 10.1182/blood-2025-8241

Abstract Background: Central nervous system lymphomas (CNSL) carry a poor prognosis and remain difficult to treat due to limited effective t...

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program

Leyla Shune, Anthony Stein, Damiano Rondelli et al. Nov 03, 2025 pp. 6008-6008 10.1182/blood-2025-6008

Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is an immune-mediated complication of allogeneic hematopoietic stem cell tr...

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Mingming Zhang, Lianxuan Liu, Yongxian Hu et al. Nov 03, 2025 pp. 1940-1940 10.1182/blood-2025-1940

Abstract Background High-risk large B-cell lymphoma (LBCL) demonstrates poor response rates and prognosis with standard chemotherapy, which...

Consolidation of dual MAPK inhibitor therapy by allograft in histiocytic sarcoma: A report of two cases

Harry Wilson, Callum Wright, Kate Milne et al. Nov 03, 2025 pp. 7330-7330 10.1182/blood-2025-7330

Abstract Introduction: Histiocytic sarcoma (HS) is a high-risk histiocytic neoplasm often involving mutations in mitogen-activated protein k...

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma

Kyle Sugg, Hyejeong Jang, Seongho Kim et al. Nov 03, 2025 pp. 7807-7807 10.1182/blood-2025-7807

Abstract Secondary primary malignancies (SPMs) are a known complication of multiple myeloma (MM) and its treatment; resulting from baseline...

RUNX1 mutations and outcomes in Acute Myeloid Leukemia: A public data-based analysis framing racial disparities in genomic risk

Jatin Thukral, Vida Tajiknia, Salman Ayub Jajja et al. Nov 03, 2025 pp. 7007-7007 10.1182/blood-2025-7007

Abstract Background: RUNX1 mutations are established high-risk features in acute myeloid leukemia (AML), associated with poor response to in...

Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy

Emmanuel Bugarin Estrada, Henry Becerra, Roger Pearse et al. Nov 03, 2025 pp. 5803-5803 10.1182/blood-2025-5803

Abstract Background: The CAR-HEMATOTOX score (HTx) is a validated tool for predicting the risk of severe cytopenias following CAR-T cell the...

Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy

Ari Pelcovits, Makayla Pardo, Diana Treaba et al. Nov 03, 2025 pp. 5327-5327 10.1182/blood-2025-5327

Abstract Introduction. The tumor microenvironment (TME) plays a central role in the efficacy of T cell-engaging immunotherapies, including C...

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

Ashish Gupta, Akshay Sharma, Haydar Frangoul et al. Nov 03, 2025 pp. 2532-2532 10.1182/blood-2025-2532

Abstract Introduction Elevated levels of fetal hemoglobin (HbF) ameliorate sickle cell disease (SCD) manifestations. BEAM-101 is an investig...

Metabolic reprogramming of megakaryocyte subpopulations in ITP: Implications for TSPO in predicting response to TPO-RA

Yu Hou, Wanru Wang, Lingjun Wang et al. Nov 03, 2025 pp. 3014-3014 10.1182/blood-2025-3014

Abstract Background Single-cell sequencing has revolutionized our understanding of the versatile nature of megakaryocyte subpopulations, amo...

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Sairah Ahmed, Matthew Mei, Jinwen Cao et al. Nov 03, 2025 pp. 5938-5938 10.1182/blood-2025-5938

Abstract Sairah Ahmed1*, Matthew Mei2* *co-first authors Introduction Classical...

Novel epitranscriptomic biomarker discovery through ensemble analysis and multi-omics integration in AML

Dona Hasini Vathsalya Gammune, Doan Bui, Tongjun Gu Nov 03, 2025 pp. 1701-1701 10.1182/blood-2025-1701

Abstract Acute Myeloid Leukemia (AML) is a biologically heterogeneous and clinically aggressive malignancy characterized by poor survival an...

Diagnostic challenges in adult hemophagocytic lymphohistiocytosis: A case series

Aaqid Siraj Syed, Warda Shahnawaz Nov 03, 2025 pp. 6565-6565 10.1182/blood-2025-6565

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory condition marked by non-specific symptoms like feve...

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

Katie Erdos, Mlaak Rob, Majed Al-Nazer et al. Nov 03, 2025 pp. 2043-2043 10.1182/blood-2025-2043

Abstract Background: The optimal treatment of early primary myelofibrosis (PMF) – prefibrotic PMF (prePMF) or low/intermediate-1 (int-1) ris...

Social support and barriers to medication adherence among adolescents and young adults with leukemia and lymphoma

Katia Crisler, Robin Norris, Tyler Ketterl et al. Nov 03, 2025 pp. 2706-2706 10.1182/blood-2025-2706

Abstract Background: Medication nonadherence is demonstrated by up to 60% of adolescents and young adults (AYAs) with leukemia and lymphoma...

Upfront therapy with allogeneic hematopoietic stem cell transplantation versus DNA methyltransferase inhibitors in patients with vexas syndrome: A comparative matched cohort efficacy analysis of 39 patients

Saubia Fathima, Ali Alsugair, Kimberly Langer et al. Nov 03, 2025 pp. 981-981 10.1182/blood-2025-981

Abstract Background: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a hemato-inflammatory syndrome due to soma...

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models

Jun Wei, Richard Jones, Isere Kuiatse et al. Nov 03, 2025 pp. 388-388 10.1182/blood-2025-388

Abstract Background: Treatment resistance and relapse in myeloma and lymphoma are driven by diverse immunosuppressive mechanisms within the...

Comparing the outcomes of autologous versus allogeneic stem cell transplant as consolidative and relapsed/refractory treatment in peripheral T-cell lymphomas

Aaron Trando, Nihaal Reddy, Aaron Goodman et al. Nov 03, 2025 pp. 7824-7824 10.1182/blood-2025-7824

Abstract Introduction: The role of hematopoietic stem cell transplant remains undefined in the treatment of many peripheral T-cell lymphoma...

Characterization of gut microbiota and metabolomics in patients with Acute Myeloid Leukemia for journal publication requirements

Ziyi Hao, Xiaotian Yang, Yejun Si et al. Nov 03, 2025 pp. 7008-7008 10.1182/blood-2025-7008

Abstract ObjectiveThis study utilizes 16S rDNA gene sequencing technology and LC-MS/MS technology to examine the gut microbiota composition...

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Yuqin Song, Qingqing Cai, Ye Guo et al. Nov 03, 2025 pp. 3740-3740 10.1182/blood-2025-3740

Abstract Introduction: A variety of treatments options are available for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) a...

Alternate dosing schedules of BCMA-directed T cell engagers display altered pathways of relapse in syngeneic vk*MYC multiple myeloma

Erin Meermeier, Caleb Stein, Meaghen Sharik et al. Nov 03, 2025 pp. 913-913 10.1182/blood-2025-913

Abstract Background: B-cell maturation antigen (BCMA)-targeted T cell engagers (TCEs) have emerged as a highly potent immunotherapy for rela...

Evaluation and validation of automated multiplexed immunofluorescence for clinical lymphoma diagnoses

Joseph Lownik, Antonio Sorrentino, Anton Villamejor et al. Nov 03, 2025 pp. 5343-5343 10.1182/blood-2025-5343

Abstract B-cell lymphomas encompass a wide range of malignancies, with clinical features ranging from indolent to aggressive. The diagnosis...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page